3.64 +0.02 (0.55%)
After hours: 5:13PM EST
|Bid||3.46 x 4000|
|Ask||3.78 x 4000|
|Day's Range||3.5900 - 3.8300|
|52 Week Range||3.3100 - 10.5400|
|Beta (3Y Monthly)||5.27|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Based in Radnor, Marinus Pharmaceuticals is studying a potential treatment for postpartum depression and acute epilepsy.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 11) Imprimis Pharmaceuticals Inc (NASDAQ: IMMY ) OvaScience ...
A handful of micro-cap stocks were making moves Monday, with the release of clinical trial results being the catalyst. Marinus said the Phase 2 trials that evaluated intravenous and oral ganaxolone for women with postpartum depression, or PPD, produced positive results.
Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
The Radnor, Pennsylvania-based company said it had a loss of 27 cents per share. Marinus Pharmaceuticals shares have dropped 38 percent since the beginning of the year. The stock has dropped 16 percent ...
A look at the shareholders of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...
Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018
On a per-share basis, the Radnor, Pennsylvania-based company said it had a loss of 24 cents. Marinus Pharmaceuticals shares have declined 14 percent since the beginning of the year. The stock has nearly ...
The biotech space represents a gold mine of opportunity for investors to multiply their investment returns, courtesy of the volatility generated by market-moving catalysts. In a note this week, Canaccord ...
The best-looking trading group right now is the small oil stocks, but even those have thinned out after a few days of strong action. There are also a few biotech names making an effort to turn, but that's sparse, too. PFE also said that it's going to suspend drug-price increase that went into effect July 1 and will keep them on hold there until President Donald Trump unveils his plan to strengthen the U.S. health-care system.
Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) is a developer of ganaxolone, a therapy intended to treat patients with a rare genetic disorder, and initial data is "looking good," according to Ladenburg ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 23) ABIOMED, Inc. (NASDAQ: ABMD ) ArQule, Inc. (NASDAQ: ARQL ) Crispr ...
The Radnor, Pennsylvania-based company said it had a loss of 15 cents per share. The company's shares closed at $4.50. A year ago, they were trading at $1.38. _____ This story was generated by Automated ...
Sage jumped Tuesday after rival Marinus said it would delay top-line results of a Phase 2 study in postpartum depression.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...